Leqembi: What Patients Need to Know

Leqembi is the brand name for lecanemab, a medicine used for certain people with early Alzheimer’s disease. It is not a cure, but it may help slow progression in carefully selected patients who can complete testing, infusion treatment, and regular safety monitoring.

What Leqembi Is and Who It Is For

Leqembi is the brand name for lecanemab, a laboratory-made antibody used in the treatment of Alzheimer’s disease. It is designed for people in the early symptomatic stages of the condition, typically those with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia. In simple terms, it is meant for patients who are having memory or thinking changes but are still in an earlier phase of illness.

Leqembi is not a cure for Alzheimer’s disease. It does not bring brain cells back or fully restore memory and thinking abilities that have already been lost. Its role is to slow disease progression in selected patients by targeting amyloid, a protein that builds up in the brains of many people with Alzheimer’s disease.

This distinction is important for patients and families. Many people ask whether Leqembi can “treat Alzheimer’s.” The most accurate answer is that it may modestly slow worsening in appropriately chosen patients, rather than stop the disease completely. Decisions about treatment are usually made after a careful neurologic assessment and a discussion of expected benefits, risks, logistics, and goals of care.

How Leqembi Works

Leqembi belongs to a group of medicines called anti-amyloid monoclonal antibodies. These medicines are designed to attach to amyloid-beta, a protein associated with plaque buildup in the brain. By helping remove this protein, Leqembi aims to reduce one of the biological features linked to Alzheimer’s disease.

However, amyloid is only one part of a complex condition. Alzheimer’s disease also involves inflammation, nerve cell injury, and other abnormal proteins. That is why reducing amyloid does not fully eliminate symptoms or guarantee the same result for every patient. The response can vary from person to person.

Because Leqembi targets a specific Alzheimer’s-related process, doctors usually confirm that amyloid is present before starting treatment. This may be done with specialized tests such as amyloid PET imaging or cerebrospinal fluid analysis, depending on local practice and the patient’s overall evaluation.

Who May Be Eligible for Leqembi

Leqembi is generally considered for people with early symptomatic Alzheimer’s disease who have evidence of amyloid in the brain. A person with advanced dementia is not usually the intended candidate for this therapy. Eligibility depends not only on diagnosis, but also on overall health, MRI findings, medications, and the ability to attend repeated infusion visits and follow-up scans.

Doctors also look closely at conditions that may affect safety. For example, a history of certain types of brain bleeding, significant abnormalities on MRI, or use of some blood-thinning medicines may influence whether treatment is appropriate. A person’s genetic background, including APOE status, may also be discussed because it can affect the likelihood of treatment-related brain changes.

Since memory problems can have many causes, a careful workup matters. Specialists may need to distinguish Alzheimer’s disease from other causes of cognitive decline, including vascular disease, depression, medication effects, sleep disorders, or other neurodegenerative conditions. Patients undergoing this kind of evaluation may benefit from a broader review of Alzheimer’s disease and related testing pathways.

Benefits Patients Can Realistically Expect

The main potential benefit of Leqembi is slowing the rate of decline. For some patients, that may mean a longer period of maintaining daily activities, communication, routines, or independence than might otherwise occur. These changes are often gradual, so the benefit may not feel dramatic from week to week.

It is important to set realistic expectations. Leqembi is not expected to improve memory back to normal or stop all progression. Some people and families may notice little visible change, even when the treatment is having a biological effect. Others may feel that preserving function for longer is meaningful and worthwhile.

Patients and families often find it helpful to ask practical questions: What goal matters most right now? Is the aim to preserve daily function, stay at home longer, or support memory for a period of time? A specialist can help weigh whether the likely benefit matches the effort and monitoring that treatment requires.

Risks, Side Effects, and MRI Monitoring

The best-known risk with Leqembi is ARIA, short for amyloid-related imaging abnormalities. ARIA can appear on MRI as brain swelling or small areas of bleeding. In many cases it causes no symptoms and is found only because routine brain scans are performed. In other cases, it can cause headache, confusion, dizziness, nausea, vision changes, or difficulty walking.

Because of this risk, MRI monitoring is a central part of treatment. Patients usually have brain MRI scans before starting therapy and again at scheduled points during treatment. If ARIA is found, the medical team may pause treatment, repeat imaging, or decide that continuing is not safe. The exact plan depends on the severity of findings and whether symptoms are present.

Other possible side effects include infusion-related reactions such as fever, chills, flushing, nausea, or changes in blood pressure during or after the infusion. Patients should promptly report any new neurologic symptoms, especially severe headache, confusion, weakness, seizures, sudden balance problems, or unusual visual symptoms. If a patient has questions about broader evaluation of memory loss, neurology assessment can help guide diagnosis and treatment planning.

• Common concerns discussed before treatment include ARIA, infusion reactions, and the need for repeated MRI scans.
• Risk may be higher in some patients, including those with certain genetic factors or brain MRI findings.
• Any sudden or concerning neurologic symptom should be reviewed urgently by a clinician.

How Treatment Is Given and What the Process Involves

Leqembi is given by intravenous infusion, meaning it is delivered through a vein at regular intervals in a supervised medical setting. This makes treatment more involved than taking a daily pill. Patients usually need coordinated appointments for infusions, check-ins, and scheduled MRI scans.

Before treatment begins, the care team typically confirms the diagnosis, reviews medical history, checks current medications, and arranges testing to document amyloid. Brain MRI is especially important to identify pre-existing findings that may increase treatment risk. Some patients may also have cognitive testing, laboratory studies, and consultation with dementia specialists.

During treatment, follow-up remains essential. The team monitors for side effects, changes in memory or function, and any new neurological symptoms. Families often play a central role by observing day-to-day changes and helping the patient keep appointments. In some settings, care may involve memory clinics, infusion services, radiology, and specialists in brain and nerve check-up pathways.

Questions to Discuss Before Starting Leqembi

Because Leqembi involves both potential benefit and meaningful monitoring, shared decision-making is especially important. Patients and families may want to discuss what stage of disease is present, how certain the diagnosis is, whether amyloid has been confirmed, and how likely the treatment is to fit the patient’s goals and routine.

It is also reasonable to ask about practical issues. These include how often infusions are needed, how many MRI scans are expected, what symptoms should trigger an urgent call, and whether other health conditions could increase treatment risk. A review of current medicines is particularly important, especially if the patient takes blood thinners or has a history of stroke or brain bleeding.

Supportive care should remain part of the conversation. Cognitive rehabilitation, sleep optimization, exercise, hearing correction, mood treatment, and caregiver support can all matter alongside medication. For patients being assessed for cognitive decline, evaluation in specialized neurosciences services may be helpful when imaging or other brain conditions need expert review.

When to Seek Medical Care

A person taking Leqembi should seek medical advice promptly if new symptoms develop after an infusion or between visits. Symptoms that deserve timely attention include worsening confusion, severe headache, dizziness, fainting, new vision changes, trouble speaking, weakness, seizures, or unusual difficulty walking. These symptoms do not always mean a serious complication, but they should not be ignored.

Routine medical review is also important if memory or daily function is changing, even without sudden symptoms. Follow-up helps the care team decide whether treatment is still appropriate and whether additional support is needed at home. Caregivers should feel comfortable raising concerns early, since small changes in behavior or function can be clinically useful.

For international patients who need multidisciplinary evaluation, Acibadem International’s JCI-accredited hospitals provide diagnosis and treatment through specialist neurology and neurosciences teams. A qualified doctor can help determine whether Leqembi is suitable, whether additional testing is needed, and what follow-up plan is safest for the individual patient.

Frequently asked questions

Is Leqembi a cure for Alzheimer’s disease?

No. Leqembi is not a cure, and it does not reverse Alzheimer’s disease. It may help slow worsening in some people with early symptomatic Alzheimer’s disease who meet treatment criteria.

Who is usually considered for Leqembi treatment?

Leqembi is generally considered for people with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia. Doctors usually confirm amyloid in the brain and review MRI results, overall health, and medication use before deciding.

How is Leqembi given?

Leqembi is given by intravenous infusion in a monitored medical setting. Treatment also involves scheduled follow-up visits and MRI scans to watch for side effects such as ARIA.

What is ARIA and why does it matter?

ARIA stands for amyloid-related imaging abnormalities, which can include brain swelling or small areas of bleeding seen on MRI. It is important because it may occur during treatment, sometimes without symptoms, and can occasionally become serious.

Do all patients with memory loss need Leqembi?

No. Memory problems can happen for many reasons, and Leqembi is only appropriate for certain patients with confirmed early Alzheimer’s disease. A careful evaluation helps determine the cause of symptoms and whether this medicine is a good fit.

Can Leqembi be used together with other Alzheimer’s treatments?

Sometimes, depending on the individual treatment plan and the patient’s overall health. The treating doctor will review current medicines, potential interactions, and whether combination management is appropriate.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.